← Leaderboards
Michael Conte
Humacyte, Inc.
$1,570,756
Attributed
$1,570,756
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $566.2K · FY2014–16$1M$750K$500K$250K$0
'14
'15
'16
Funding mix
By agency
NIH$1,570,756 · 1
By mechanism
N01$1,570,756 · 1
Top collaborators
No co-investigators on record.
Most similar at Humacyte, Inc.
Same institution · by research overlap
- Shannon L. M. Dahl$2,424,736
- Ted Lithgow$1,949,134
- Robert David Kirkton$217,277
Others in their field
Top investigators on “Autologous”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$46,791,890
- Mary M Horowitz · Medical College Of Wisconsin$38,654,527
- Louis J. Picker · Oregon Health And Science University$32,726,954
- David Wofsy · University Of California, San Francisco$31,423,453
- Douglas F Nixon · J. David Gladstone Institutes$28,670,832
Research focus
AutologousBlood VesselsBypassClinical ApplicationCollagenContractsDesignDiagnosticDialysis ProcedureHyperplasiaImmune ResponseInnovationKneeMedicalModalityNational Heart, Lung, And Blood InstituteOperative Surgical ProceduresPeripheralPeripheral Arterial DiseasePeripheral Vascular DiseasesPhase 1 StudyProduct DevelopmentProgramsPulmonary Hypertension
Grant awards (3)
IGF::OT::IGF VASCULAR INTERVENTIONS/INNOVATIONS ANDTHERAPEUTIC ADVANCES (VITA): BIOENGINEEREDGRAFTS FOR PERIPHERAL VASCULAR DISEASE FOR BASEPERIOD: NOVEMBER 15, 2013 - NOVEMBER 14, 2014$478,270
N01 · FY2016 · HL · contact PI
IGF::OT::IGF VASCULAR INTERVENTIONS/INNOVATIONS ANDTHERAPEUTIC ADVANCES (VITA): BIOENGINEEREDGRAFTS FOR PERIPHERAL VASCULAR DISEASE FOR BASEPERIOD: NOVEMBER 15, 2013 - NOVEMBER 14, 2014$566,202
N01 · FY2015 · HL · contact PI
IGF::OT::IGF VASCULAR INTERVENTIONS/INNOVATIONS ANDTHERAPEUTIC ADVANCES (VITA): BIOENGINEEREDGRAFTS FOR PERIPHERAL VASCULAR DISEASE FOR BASEPERIOD: NOVEMBER 15, 2013 - NOVEMBER 14, 2014$526,284
N01 · FY2014 · HL · contact PI